Clovis Oncology (NASDAQ:CLVS) today announced preliminary Phase 2
results from the ARIEL2 ( A ssessment of R ucaparib I n
Ovarian Canc e r Tria l ) study and updated results from the
ongoing Phase 1/2 monotherapy study of rucaparib.
for Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy investment picks